HEALTH

New England Patriots’ offensive line receives Prilosec OTC-sponsored award

BY Michael Johnsen

CINCINNATI — NFL commentator John Madden and the Prilosec OTC team on Thursday awarded the New England Patriots’ offensive line the 2010 Madden Most Valuable Protectors Award, presented by Prilosec OTC.

"The offensive line doesn’t always catch the fans’ attention, so Prilosec OTC and I created this award to recognize the guys who provide the critical run blocking and pass protection," Madden stated. "All season long, these guys proved they had the mental and physical toughness that enabled the Patriots offense to put up impressive numbers on the ground and in the air."

Madden and company presented the award during a press event in Texas. Accepting the trophy on behalf of the New England Patriots were offensive linemen Dan Koppen, Dan Connolly and Mark LeVoir.

The award is based on a combination of criteria including offensive line statistics — sacks allowed, rushing and passing yardage, time of possession, O-line penalties, third and fourth down conversion percentages and red zone scoring conversions, fan voting and coach Madden’s own personal observations throughout the season.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Intimate Bridge 2 Conception developing an OTC take-home insemination device

BY Michael Johnsen

PITTSBURGH — A private entrepreneur is close to introducing a take-home intracervical insemination fertilization kit to retail, according to a story published in the Pittsburgh Post-Gazette Friday. The product will be submitted for Food and Drug Administration approval in the first half of 2011. If approved, Steve Bollinger first plans to introduce the product into doctor’s offices before launching through retail pharmacy.

Bollinger, CEO of Intimate Bridge 2 Conception, hopes to introduce Focus Touch at an $80 price point by the end of the year, following FDA approval. Bollinger already has raised $500,000 in investments from the Pittsburgh Life Sciences Greenhouse and local incubator Innovation Works, the Post-Gazette reported, and expects to close on a second round of funding worth $1.5 million in March.

The Focus Touch is designed to allow do-it-yourself intracervical insemination, a process that places semen right near the cervix to increase the chance of a pregnancy. The kit will include a specially designed condom to collect the semen in a small cap; the small cap is then removed and fitted onto a long, thin tube for insemination. “The cap can stay inside the woman’s body for three to five hours before being pulled out by a string, much like a tampon,” the paper reported.

The cap also can be stored in a refrigerated climate for up to seven days.

Intracervical insemination has a success rate of 10% to 15%, Bollinger reported.

Walgreens vet Michael Tovian, a one-time VP managed care sales and contracting, sits on IB2C’s board.

For the complete story, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

C.NOLAN says:
Aug-01-2013 10:45 pm

How was this project going? Did the company have the device already? If yes, what are the progress and benefits it contributed to the company? I have heard that they will also build a bridge but they still have to present approval to bid & certifications to be used for the products during delivery from different places.

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Puralube re-enters market

BY Michael Johnsen

NEW YORK — Fera Pharmaceuticals on Wednesday announced the reintroduction of the nonprescription dry-eye remedy Puralube ophthalmic ointment due to demand for the product.

“Puralube is a product that fits perfectly with our eye care portfolio,” stated Frank DellaFera, president of Fera. “We are so pleased to make Puralube available again, giving patients, pharmacists and physicians a cost-effective and reliable treatment option for dry-eye symptoms.”

Fera is launching Puralube in a 3.5-g tube and a carton of 20 1-g tubes. It will be available through retail, wholesale and mail-order pharmacy, the company stated.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?